However, while usually described as an antagonist, Ex4(9-39) has also been described as an inverse agonist at the murine GLP-1R (Serre et al ., 1998)
Images were analysed using ImageJ software
Shilpa Paradkar Singh, MD | Last reviewed June 2026 Access to the latest FDA-approved medications tailored to your biology
Given that obesity is a chronic and relapsing disease, it is important to understand the effectiveness of different strategies to maintain WL: TRIUMPH-6 (NCT06859268) will assess changes in bodyweight at 116 weeks in individuals with obesity who have completed 80 weeks of retatrutide, comparing continued treatment at high or low doses of retatrutide versus switching to placebo for the last 36 weeks
In other words, manipulating a prescription outside of the intended use or extending it may cause safety concerns and consequences unaccounted for in research studies. If its unsafe to use any leftover medication in the pen after four weeks of injections, GLP-1 users may wonder whats the safest way to dispose of it
GLP-1 binds receptors on beta cells
